EP Patent

EP4598512A1 — Immediate release oral pharmaceutical composition comprising linagliptin

Assigned to Santa Farma Ilac Sanayi AS · Expires 2025-08-13 · 1y expired

What this patent protects

The present invention relates to an oral immediate-release pharmaceutical composition comprising therapeutically effective amount of linagliptin or pharmaceutically acceptable forms or derivatives thereof. More specifically, the present invention relates to a solid oral dosage fo…

USPTO Abstract

The present invention relates to an oral immediate-release pharmaceutical composition comprising therapeutically effective amount of linagliptin or pharmaceutically acceptable forms or derivatives thereof. More specifically, the present invention relates to a solid oral dosage form manufactured by direct compression method presenting improved physicochemical characterizations along with release and impurity profiles.

Drugs covered by this patent

Patent Metadata

Patent number
EP4598512A1
Jurisdiction
EP
Classification
Expires
2025-08-13
Drug substance claim
No
Drug product claim
No
Assignee
Santa Farma Ilac Sanayi AS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.